Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions (NCT05927272) | Clinical Trial Compass
UnknownNot Applicable
Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
France10 participantsStarted 2024-04-10
Plain-language summary
The purpose of this study is to perform an in-depth analysis of the molecular pathways involved in lesions responding to current treatment and lesions not responding to current treatment
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject: male or female aged ≥ 18 years and ≤ 65 years
* Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved \>5% excluding hands and feet, with lesions located on arms
* Active non-segmental vitiligo is defined by:
* Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND
* Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination.
* Able to read, understand, and give documented informed consent
* Registered in the French Social Security
* Patients that could receive the combination of oral steroids and phototherapy according the recommendation
* Signed informed consent form
Exclusion Criteria:
* Segmental or mixed vitiligo
* Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures.
* Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
What they're measuring
1
Evaluate the evolution of skin biological pathways, assessed by single cell RNAseq in the peri-lesional and lesional skin of a target lesion